Prof Dr John N Giannios

DiplEngl(NYU), BSc(Biol)(USA), BSc(Chem)(USA), CertGCP(London),

PGCertTMed(Edinburgh), PGDiplTMed(Edinburgh), MScTMed(Edinburgh), MD(AM) MPhil

Med(London), PgCertFMed(Glasgow), cDSc(London), cLLB(Aberdeen), BCAM(USA), MD(AM)(Cal),

FRSM(London), MRSC( Cambridge) and M/D Prof (London) in translational cancer medicine.

The four postgraduate degrees in translational medicine were obtained with distinction from

The four degrees in Translational Surgery in Translation Medicine were awarded with distinction by the Universities of Edinburgh and London Medical School. He is the project leader of the

Translational Cancer Medicine in University Medical Hospitals discovering as

as a cancer researcher discovering new personalised treatment approaches

genomic/epigenomic medicine, molecular diagnostics based on

pharmacogenomics and molecular oncology research involving nanomedicine,

nanosurgery and oncogenomics/epigenomics.

He is discovering by next-generation sequencing at US Medical Universities new cancer-related genes as targets for novel diagnostic and biological therapies in the context of a personalized approach to cancer medicine based on pharmacogenomics, pharmacogenomics and oncotherapeutics.

In addition, he is a genomic consultant for preventive oncology including hereditary cancers, screening, diagnosis and oncotherapy for personalized anticancer therapy based on the genomic and epigenomic profile of the tumor.

He is president and editor-in-chief of the Hellenic and International Society for Molecular and Genomic Medicine and Research, organizing three national oncology conferences with international participation to date.

He also heads the Translational ResearchConference of the American Society of Biomedical Sciences and is a member of the executive editorial board of journals such as EC Cancer journals etc. He is the president of the International Academy of Precision Medicine and Oncology and president of the International College of P4 Medicine based Clinical Medicine.

In addition, he is president of the International Association for Personalized Perioperative Medicine and Laser, Robotics and Genomic Nanomedicine. In particular,he has invented many new cancer therapies based on molecular oncology and nanosurgery after adjuvant therapy facilitated by nanomedicine with a focus on nano-oncology and fem second laser that leads to the elimination of cancer stem cells by nanophotothermolysis.

He has also invented several stem cell therapies for regenerative medicine which he has presented at American conferences and in Canada. He has organized as chairman of the scientific and organizing committee of many molecular oncology conferences. He is a member of the editorial board of several international medical journals such as e-cancer etc.

He has about 3,000 CME credits from Harvard University School of Medicine and other leading American medical universities such as John Hopkins, University of Alabama, etc. He holds certificates of achievement for completing 144 credit hours in Category 1 of the American Medical Association’s Physician Recognition Award and medical course certificates covering all medical subspecialties of 50 credit hours each after passing an examination given by the American College of Physicians-American Society of Internal Medicine. He has also passed board certification exams with medical units from the American College of Surgeons where he has a three-year residency in thoracic surgery where he research perfected photodynamic therapeutic approaches (PDT) facilitated by molecularly targeted nanodelivery systems using antibodies against advanced lung cancers (NSCLC, SCLC, etc.). For this work he has been awarded by the Balkan School of Oncology and has presented them in plenary sessions of international medical laser conferences.

He has also attended breast surgeries for many years refining research approaches of molecular surgery. He is accredited by American Medical Universities to lecture to American Physicians to meet the continuing medical education [CME] requirements required by the American Medical Boards for recertification.

He has been selected for inclusion in Who is Who in Medicine , and has been elected by the International Biographical Centre in Cambridge as a leading scientist in scientific research worldwide.

He has been a thought leader for the past two decades in genomic and epigenomic cancer medicine, where he has authored four books and more than 5. 000 lectures, posters and publications in international oncology conferences and journals with more than 500 awards in new therapies based on personalized cancer medicine and translational medicine, including oncology, cardiology, regenerative medicine,endocrinology, gynecology, neurology and other medical subspecialties where omic technology and nanomedicine could be applied in particular to tailor personalised treatments for cancer patients with incurable solid tumours such as glioblastoma multiforme and metastatic tumours, applying molecular targeting approaches to bypass chemo/radio/immunoresistance mechanisms using antisense therapies to down-regulate anti-apoptotic oncogenes and gene therapy or epigenetic therapy to re-express silenced tumour apoptotic suppressor genes.

The induction of the irreversible stage of D2 apoptosis is monitored by electron microscopy where he has extensive experience from the University of London.

Professor Ioannis Giannios has contributed as a genomic advisor to the national genomic guidelines for breast cancer screening, diagnosis and treatment. He has teaching experience in many government (public) and private oncology hospitals where he has directed cancer research with genomic approaches with a focus on personalized medicine for cancer.

Finally, he is a founding and active member/member of many medical societies such as International Society of Gastrointestinal Oncology (ISGIO), European Society of Gynecologic Oncology (ESGO), American Society of Clinical Oncology (ASCO), The American Association for Cancer Research (AACR), the International Academy of Legal Medicine (IALM), the European Society of Human Genetics (ESHG), the National Society of Genetic Counselors (NSGC), etc. etc.

He is qualified to teach and translationally apply all therapeutic approaches of personalised medicine, where as a translational medicine practitioner he can take these new therapies from the bench to the clinic. He has invented the genomic therapeutic vaccine against cervical Ca caused by HPV virus and presented at ASCO (USA). He has invented a new therapeutic method of anti-cancer vaccines such as genomic therapeutic vaccines and autologous anti-cancer vaccines in personalized medicine.

He has discovered many new anti-cancer therapies, establishing the personalized omics-based approach to cancer medicine, which is contrary to the blind policy of big pharmaceutical companies’ one-size-fits-all policy.

He is the inventor of immunotargeted NANOSURGERY for the elimination of cancer metastases as presented at ISGIO and the 29th Panhellenic Congress of Surgery pioneering the best and most effective future surgical oncology.

It is now in the process of eliminating glioblastoma multiforme cells (the most lethal tumor called terminator) and glioma cerebri (called as ghost in the brain) with molecular robotic nano surgery facilitated by RFDH, personalized cancer vaccines and stem cells encoded with antisense molecules which have been presented at American oncology conferences such as SNO .

He is board certified in Alternative and Integrative Medicine in the US and UK. He is also an editor in American medical journals. He is one of the founding academic members who created OMICS-based PRECISION CANCER MEDICINE, which was facilitated by nanomedicine by starting the presentations of these new innovative therapeutic approaches about 20 years ago to the American Society of Clinical Oncology and the American Association for Cancer Research as a member and associate in more than 100 medical societies and associations such as ISGIO, ESMO, ESGO, EACR, etc. etc. where in some of them I have acted as a founding member and from which I have won many awards for my new therapeutic strategies. Finally, I am the acting editor of the Int Journal of Cancer Therapy &amp? Oncology (CTOIJ) USA , Editor of the Journal of Cardiology & Cardiovascular Therapy (JOCCT) USA, Editorial Board Member of the CLINICAL CASE REPORTS and REVIEWS JOURNAL (London,UK), EDITOR of the Open Access JOURNAL OF SURGERY (USA) and Head of the Translational Medicine Assembly of the AMERICAN SOCIETY OF BIOMEDICINE.

As President of the non-profit International Association for Personalized Perioperative Medicine and Laser, Robotic and Genomic Nano-surgery, I am an experimental practitioner of Nano-surgery for the eradication of cancer stem cells, which I presented at the 2013 Annual Meeting at the 2013 Plenary Session of the International Society of Gastrointestinal Oncology in the USA and Genomic Surgery against metastatic tumors.